Fisher Asset Management LLC maintained its position in shares of Agenus Inc. (NASDAQ:AGEN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 135,204 shares of the biotechnology company’s stock at the end of the second quarter. Fisher Asset Management LLC owned approximately 0.14% of Agenus worth $529,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of AGEN. AQR Capital Management LLC bought a new position in shares of Agenus during the fourth quarter valued at approximately $143,000. SG Americas Securities LLC raised its position in shares of Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 23,689 shares during the period. American International Group Inc. raised its position in shares of Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 2,984 shares during the period. Quotient Investors LLC raised its position in shares of Agenus by 8.8% in the first quarter. Quotient Investors LLC now owns 47,000 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 3,800 shares during the period. Finally, UBS Asset Management Americas Inc. raised its position in shares of Agenus by 203.7% in the first quarter. UBS Asset Management Americas Inc. now owns 51,933 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 34,833 shares during the period. Institutional investors and hedge funds own 41.54% of the company’s stock.

Shares of Agenus Inc. (AGEN) traded up 1.71% during mid-day trading on Friday, reaching $3.57. 483,682 shares of the company traded hands. The firm has a 50 day moving average of $4.25 and a 200-day moving average of $3.90. The stock’s market capitalization is $355.97 million. Agenus Inc. has a 52 week low of $3.20 and a 52 week high of $7.49.

Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.04. Agenus had a negative net margin of 280.96% and a negative return on equity of 37,577.49%. The business had revenue of $4.21 million during the quarter, compared to the consensus estimate of $6.66 million. During the same period in the previous year, the company posted ($0.33) earnings per share. The firm’s revenue was down 36.1% on a year-over-year basis. On average, equities research analysts expect that Agenus Inc. will post ($1.13) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/19/fisher-asset-management-llc-continues-to-hold-stake-in-agenus-inc-nasdaqagen-updated-updated-updated.html.

A number of analysts have recently weighed in on the stock. BidaskClub raised shares of Agenus from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. ValuEngine raised shares of Agenus from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $7.00 target price on shares of Agenus in a research report on Friday, August 4th. Zacks Investment Research raised shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Wednesday, July 5th. Finally, HC Wainwright set a $5.00 target price on shares of Agenus and gave the stock a “hold” rating in a research report on Saturday, May 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $5.88.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Stock Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related stocks with our FREE daily email newsletter.